Multiple sclerosis (MS) diffusely abnormal white matter (DAWM) is a mildly hyperintense magnetic resonance imaging abnormality distinct from typical lesions. Our goal was to investigate the prevalence and natural history of DAWM in a large cohort (n = 348) of relapsing-remitting MS (RRMS) patients. METHODS: The presence of DAWM and relationship to changes in T 2 burden of disease (BOD), brain volume (brain fractional ratio, BFR), and disability (Expanded Disability Status Scale, EDSS) were investigated at baseline and year 7-8 (long-term follow-up, LTF).
Introduction
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS) characterized by episodic inflammatory demyelination and variable degrees of clinical progression. 1, 2 The typical magnetic resonance imaging (MRI) features of MS are discrete CNS hyperintense lesions on T 2 -weighted, proton density and fluid-attenuated inversion recovery scans, 3 which aid in clinical diagnosis and monitoring disease progression. 4, 5 CNS abnormalities beyond obvious MS plaques are also well documented. [6] [7] [8] The "normal-appearing white matter" (NAWM) is a commonly described feature of white matter that appears normal on conventional MRI, but abnormalities can be detected using advanced MRI. [9] [10] [11] [12] [13] [14] [15] [16] [17] A less often reported, but still common, feature in MS is regions of white matter with signal intensity intermediate between NAWM and MS lesions on T 2 and proton density imaging, termed diffusely abnormal white matter (DAWM) 18, 19 ( Fig 1) , formerly termed "dirty-appearing white matter." By definition, DAWM is diffuse with ill-defined borders and has signal intensity similar to gray matter on proton density and T 2 scans, but is found in white matter locations. DAWM is predominantly observed in periventricular regions and the centrum semiovale, [18] [19] [20] and typically spares the subcortical U-fibers. Quantitative MRI of DAWM yields magnetization transfer and myelin water imaging values between those of NAWM and MS lesions, 12, [20] [21] [22] [23] [24] suggesting that DAWM could represent a pathologic substrate occurring during the development and/or resolution of MS lesions, or be a separate lesion-independent entity all together. Postmortem studies of DAWM in brain and diffuse signal changes in the spinal cord find blood-brain barrier breakdown, 25 and reductions in myelin and axons. [25] [26] [27] In particular, DAWM shows a selective loss or disturbance of myelin lipids with substantial reduction of Luxol Fast Blue and Weil's staining, 22, 28, 29 believed to recognize phospholipids. [30] [31] [32] Myelin proteins, including proteolipid protein, myelin basic protein, myelin-oligodendrocyte protein, myelin-associated glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphohydrolase, are less affected 22, 28, 29 and axonal loss is moderate. 22, 28, 29 The degree of DAWM histological changes is intermediate to those found in NAWM and MS plaques. 28 DAWM is gaining recognition as a distinct entity in MS that may aid in understanding the disease and its progression. 12, 20, 33, 34 While DAWM is commonly seen in MS, its prevalence and evolution over time have not yet been assessed in a large population of patients, and neither has the relation of these changes to clinical and other MRI findings. The aim of this study was to further characterize the natural history of DAWM, assessing the changes in prevalence of DAWM in patients with MS over a long-term follow-up (LTF) of approximately 8 years. In addition, we examined the relation of DAWM to changes in T 2 lesion volume (T 2 burden of disease, T 2 BOD), brain volume (brain fractional ratio, BFR), and clinical disability (Expanded Disability Status Scale [EDSS] score).
Methods
The study was approved by the institutional clinical research ethics board. All MRI studies were performed with the understanding and full written consent of each subject.
Patients
Patients with active (at least two relapses in previous 2 years) relapsing-remitting MS (RRMS, EDSS 0-5) (n = 560) originally underwent MRI scans as part of an interferon beta-1a (IFNB1a; Rebif R , Merck Serono International S.A., Geneva, Switzerland) versus placebo treatment trial (Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis; PRISMS). Detailed patient and MRI data have been published previously. 35 Placebo-treated patients received IFN1a after 2 years. At year 2, all placebo patients were rerandomized to either 22 or 44 mcg treatment. The proportion of patients remaining on interferon therapy at LTF was similar for each of the original randomization cohorts (ie, placebo, 22 and 44 mcg). Of the original 560 randomized patients, 348 remained in the LTF study with scans at baseline and at 7-8 years after baseline. 36 Healthy volunteers with no neurological conditions (n = 67) were also scanned as controls during the initial MRI training and qualification dry runs for the original treatment trial.
MRI Assessments
All MRI studies were performed according to a protocol with strict repositioning criteria. Various scanners (GE, Siemens, and Philips), operating at field strengths from .5 to 1.5 T, were used. Twenty-four 5-mm-thick slices, contiguous (or at most with a .5 mm gap), were obtained in the axial plane from the foramen magnum to the vertex. Proton density and T 2 -weighted conventional spin echo (TR = 2,000-3,000 milliseconds, TE = 20-30 milliseconds, and 80-100 milliseconds) scans were performed every 6 months initially over 2 years.
Cranial proton density and T 2 -weighted MRI scans were performed at the initial baseline assessment and at LTF for each patient using the same acquisition parameters (pulse sequences, slice coverage, number, thickness, and gap) and strict repositioning procedures were followed. 35, 36 Digitized images were coregistered using the maximization of mutual information as the image similarity measure and sinc interpolation for resampling. 37 T 2 lesions were identified by an experienced radiologist and the total T 2 BOD was determined by trained technologists using a semiautomatic method, 35, 36 and reported as the summed cross-sectional area (in square millimeters). The BFR, which is a normalized brain volume, was derived by subtracting each patient's cerebral spinal fluid (CSF) volume from the total intradural volume and normalizing to the intradural volume.
35,36
Evaluation of DAWM Evaluation of the scans for presence of DAWM was performed at a single workstation by two experienced MRI radiologists (with 10 years and over 20 years experience) working independently and masked to the clinical course. Where there was a disagreement, a third MRI radiologist (with over 20 years experience) reviewed the scans and a final result was obtained by consensus. DAWM was defined as a region of white matter that was iso-intense to gray matter on both proton density and T 2 -weighted images, present on at least two consecutive scan slices, and measured greater than 10 mm in diameter. Determination of whether DAWM increased, decreased, or remained the same at LTF was made qualitatively through direct visual comparison of the two scans, reviewed side-by-side with baseline and follow-up scans indicated and facilitated by coregistration of the scans.
Evaluation of Clinical Disability
Physical disability was determined using the Kurtzke EDSS at the time of each MRI scan. 36 Clinical outcomes of interest included: EDSS score at baseline and LTF, change in EDSS score from baseline to LTF, and EDSS progression. An increase in the EDSS score of 1.0 point (.5 point increase if baseline EDSS > 5.5) that was confirmed at a subsequent assessment at least 3 months later was defined as EDSS progression.
Statistical Analyses
Baseline characteristics, including EDSS score, number of relapses in the previous 2 years, age at MS onset, age at study entry, and disease duration, were compared between patients with and without DAWM at baseline using the Wilcoxon ranksum test, whereas sex was compared using the Fisher's exact test. The χ 2 test was used to assess the association between the rate of DAWM and field strength. All 348 patients were included in the analysis.
Relations between presence of DAWM at baseline and the percentage change in BOD and BFR from baseline to LTF were assessed initially without adjustment for the baseline measure, using the Wilcoxon rank sum test or a t-test when appropriate, and then after adjustment for the baseline measure using the analysis of covariance (ANCOVA). Since the BOD values are highly skewed, in the ANCOVA analysis, the change in BOD was examined on a log scale, represented as the log ratio: log(BOD at LTF)-log(BOD at baseline). For BFR, the percentage change was considered.
Patients were classified into four categories according to the change in DAWM status from baseline to LTF: Relations between the change in DAWM and the change in BOD and BFR from baseline to LTF were assessed using the Kruskal-Wallis rank-sum test (or an F-test when appropriate) when not adjusted for baseline measure, and by ANCOVA when adjusted for baseline measures. EDSS score at LTF and change in EDSS score were compared between patients with and without DAWM using the Wilcoxon rank-sum test, and the Kruskal-Wallis test was used to assess the effects of DAWM changes (no DAWM, unchanged, decreased, and increased) on these variables. EDSS progression, a dichotomous variable, was described by frequency tables and Fisher's exact tests were performed to compare patients with and without DAWM at baseline, and patients with different patterns of changing DAWM status between baseline and LTF. Time to EDSS progression was compared using the log-rank tests. Analysis of BOD and BFR was done with adjustment for initial treatment regimen. For the clinical outcomes, it was decided a priori that treatment regimen would only be adjusted if differences were observed in the unadjusted comparison. As no significant differences were detected, no adjusted analysis was carried out.
Results

Baseline Demographics
The prevalence of DAWM at baseline was 25.3% (88 of 348) in the patient population. Baseline demographic information is summarized in Table 1 . Baseline sex and age demographics were similar between patients with and without DAWM. Over 70% of patients in both groups were female (DAWM: 74%; no DAWM: 72%). The mean patient age was 35.6 years in patients with DAWM and 35.3 years in those without. However, the mean age of MS onset was higher in patients with DAWM (DAWM: 29.4 years, no DAWM: 27.3 years; P = .01) and the mean disease duration was lower in patients with DAWM (DAWM: 6.2 years; no DAWM: 8.0 years; P = .02). The majority of patients had baseline scans at 1.5 T (61% @ 1.5 T, 17% @ 1.0 T, 22% @ .5 T). The DAWM detection rate varied with field strength (.5 T: 8% with DAWM, 92% without DAWM; 1.0 T: 19% with DAWM, 81% without DAWM; 1.5 T: 33% with DAWM, 67% without DAWM; P < .001). Initial treatment regimens differed slightly between the two subgroups at baseline: 23.9% of patients with DAWM and 39.5% without DAWM at baseline received INFB1a 44 mcg sc TIW, whereas 43.2% of those with DAWM and 29.2% without DAWM received the INFB1a 22 mcg sc TIW. The percentage of patients on placebo was similar between the DAWM with and without DAWM groups. Table 2 summarizes treatment randomization for patients with and without DAWM at baseline, and subsequent next phase randomization at 2 years of original placebo group. The presence of DAWM had no impact on the treatment effect of IFNB1a on clinical and MRI outcomes (EDSS progression, BOD accumulation, and BFR reduction). Representative examples of DAWM at baseline are shown in Figures 1 and 2A , and 3A. The prevalence of DAWM in the healthy control population was 6.0% (4 of 67). The healthy control population did not differ from the MS patient population in terms of age (P = .81) or sex (P = .63).
Initial treatment randomization
Present (n = 88) n (%) Absent (n = 260) n (%) No DAWM (n = 257) n (%) No Change (n = 61) n (%) Decreased (n = 25) n (%) Increased (n = 5) n (%) Overall (n = 348) n (%)
Natural History
The duration of follow up at LTF ranged from 7.0 to 7.9 years, with a mean of 7.4 years. Of the 88 patients with DAWM at baseline, at LTF, DAWM remained unchanged in 61 patients (69.3%), decreased in 25 (28.4%; including 3 patients in which DAWM had disappeared), and increased in 2 (2.3%) patients. Representative examples of LTF decreases in DAWM are shown in Figures 2B and 3B . Of the 260 patients without DAWM at baseline, only 3 (1.2%) had developed DAWM at LTF. The majority of patients had LTF scans at 1.5 T (75% @ * Although there is no significant difference in median BOD, the variation of the "No DAWM" group was much bigger, with more patients in this category having a large volume of BOD at baseline. The two-sample Kolmogorov-Smirnov test indicated that the distributions of baseline BOD clearly differed between the two groups (P-value = .0014). a Wilcoxon rank-sum test. b Two-sample t-test. BOD = burden of disease; BFR = brain fractional ratio; DAWM = diffusely abnormal white matter; LTF = long-term follow-up; Q1 = first quartile; Q3 = third quartile; SD = standard deviation.
1.5 T, 25% @ 1.0 T). The DAWM detection rate somewhat varied with field strength (1.0 T: 20% with DAWM, 80% without DAWM; 1.5 T: 27% with DAWM, 73% without DAWM; P = .20).
T 2 Burden of Disease
At baseline, although there was no difference in median BOD (P = .78) between patients with and without DAWM, BOD was clearly distributed differently between the two groups of patients (P = .0014; Kolmogorov-Smirnov test) with a much higher variation in those patients without DAWM (Table 3) . Patients with increased DAWM at LTF (including 2 patients with DAWM at baseline and 3 patients with de novo development of DAWM) tended to have the greatest increase in BOD, followed by those in whom DAWM had decreased at LTF (Fig 4A) . The difference between the four groups of patients (no DAWM, DAWM unchanged, DAWM decrease, and DAWM increase) was partly driven by the small group of patients with increased DAWM (n = 5). When the DAWM increase group of patients was excluded from the analysis, the difference decreased (P-value changed from .002 to .07). Pairwise comparisons, adjusted for baseline BOD, show that the change in BOD in the decreased DAWM group was significantly higher than the no DAWM (P = .025) and tended to be higher than the DAWM unchanged group (P = .14). Adjusting for treatment had no notable impact on the analysis results.
Brain Fractional Ratio
While patients with DAWM had higher BFR at baseline (P < .001), perhaps related to these subjects having a shorter disease duration than patients without DAWM, patients with DAWM had a greater mean percentage reduction in BFR at LTF (Table 3 ; -4.8% vs. -4.2%; P = .17 [unadjusted] ; P = .038 when adjusted for baseline BFR). When patients were subdivided according to their change in DAWM status over time, the mean percentage change in BFR was different (P = .037 when adjusted for baseline BFR), with patients with decreased DAWM at LTF having the highest decrease (Fig 4B) . Pairwise comparisons, adjusted for baseline BFR, show that the change in BFR in the decreased DAWM group was significantly higher than the no DAWM (P = .008) and tended to be higher than the DAWM unchanged group (P = .107). Adjusting for treatment had no notable impact on the analysis results.
Expanded Disability Status Scale
There was no difference in baseline EDSS, end of study EDSS, or EDSS progression in patients with and without DAWM. Although, overall, there were no significant differences in clinical disease measures between patients according to the change in DAWM status at LTF, there was a trend (P = .055) toward a greater proportion of patients with EDSS progression in those with decreased DAWM compared with those with no change in DAWM (Table 4) .
Discussion
In our study population of RRMS patients with an average disease duration of 7.5 years at the start of the study, DAWM was present in approximately one quarter of participants (25.3%) at baseline; in comparison, DAWM was identified in only 6.0% of the control population. The pathological basis for these changes in supposedly normal and healthy subjects is unknown but may relate to underlying subclinical vascular disease or other subclinical white matter pathology. 38 DAWM tended to remain stable over an ß8-year follow-up period, and only 1% of patients without DAWM at baseline went on to develop this abnormality. Although the presence of DAWM had no impact on the treatment effect of IFNB1a on clinical and MRI outcomes, it is not known whether IFNB1a treatment may have prevented the development of DAWM, as the majority (72%) of patients in the study remained on IFNB1a at the LTF assessment. 36 
Possible Etiologies of DAWM
The abnormalities in myelin phospholipids previously demonstrated postmortem 22, 27, 29 could indicate that DAWM identifies A trend toward greater EDSS progression and a greater increase in EDSS score was seen in patients with decreased DAWM at long-term follow-up as compared with patients with no change or no DAWM. Patients with increased DAWM were not included as the sample size was too small (n = 5). a Wilcoxon rank sum test. b Fisher's exact test. c Log-rank test. d An increase in the EDSS score of 1.0 point (.5 point increase if baseline EDSS > 5.5) that was confirmed at a subsequent assessment at least 3 months later was defined as EDSS progression. DAWM = diffusely abnormal white matter; EDSS = expanded disability status scale; n = number of patients; SD = standard deviation.
a unique subgroup of patients with MS with an inherent and/or acquired defect in myelin lipids, potentially making their white matter more vulnerable to autoimmune attack, inflammation, and myelin loss. Supporting this hypothesis is our observation that patients with decreases in DAWM area, who made up ß1/3 of all DAWM positive patients, had greater increases in T 2 BOD and larger decreases in BFR than both no DAWM and DAWM unchanged participants. We postulate that loss of brain volume over time was greatest in patients with decreasing DAWM because of expansion of T 2 lesions into space formerly occupied by DAWM (ie, replacement of DAWM by lesions) and/or ventricular enlargement (Figs 2B and 3B). If our theory is correct, these findings suggest that DAWM may be an important predictor of MRI disease evolution. This interpretation is in line with recent work by Dwyer et al who found that atrophied lesion volume (ie, a reduction of lesion load due to atrophy and progressive ventricular enlargement) over 5 years was greatest in progressive MS, and was the only significant correlate of EDSS change, while neither new lesion volume nor development of whole brain atrophy was related to disability progression. 39 This work also supports our observation of a trend toward a greater proportion of patients with EDSS progression in those patients with decreased DAWM compared with those with no change in DAWM (P = .055).
Alternatively, DAWM may reflect impaired lymphatic drainage of the brain with potentiation of the inflammatory response in a subset of MS patients. Findings of widened perivascular spaces that contain inflammatory-cell infiltrate in DAWM support this hypothesis. 25 Furthermore, this observation could help to explain the posterior periventricular predominance of DAWM.
A third possibility, and likely not the last, is that DAWM is a mild form of vasogenic cerebral edema, without mass effect, that occurs either independently from or secondary to vascular changes in the plaque. Blood-brain barrier breakdown, the basis of vasogenic edema, does occur in DAWM. 25 It is possible that this increased barrier permeability may allow the introduction of a circulating myelinotoxic molecule from the systemic circulation to induce the lipid changes in myelin in DAWM.
DAWM and Progression
Although there was a near significant trend toward greater EDSS progression at LTF in patients with decreased DAWM (P = .055), overall there was no significant relation, in crosssection or longitudinally, between the presence of DAWM or changes in DAWM and EDSS. As EDSS is primarily a measure of physical disability, it does not accurately capture many other symptoms of MS. Given the typical location of DAWM (mainly central, involving the posterior periventricular white matter and, to a lesser extent, the centrum semiovale), DAWM may be more likely related to impairments in cognitive processing, calculation, or visuo-spatial tasks; therefore, a lack of relation between EDSS and DAWM is not unexpected.
Limitations
When considering our findings, the study limitations should be taken into account. The study population was heterogeneous with respect to the treatment regimens: the initial randomization to different interferon beta-1a doses did not consider the presence or absence of DAWM. Furthermore, DAWM by nature is ill-defined and, thus, assessment of changes in DAWM over time using historical data collected at field strengths ࣘ1.5 T was qualitative and subjective. Determination of whether DAWM increased, decreased, or remained the same at longterm follow-up was made through direct visual comparison of the two scans, reviewed side-by-side with baseline and followup scans indicated. The accuracy of the qualitative observations was improved by DAWM assessment by two, and occasionally three, independent experienced MRI MS neuroradiologists, and by coregistration of the scans, whereby corresponding cursor locations on the scans could easily be identified and new locations of DAWM could be confirmed. We did not assess a percentage change because it was very difficult to quantitate and identify a definitive border of DAWM. It is because of these poorly defined borders, DAWM is usually excluded from quantitative volume measurements of MRI disease burden. The dashed line surrounded by a diffuse gradient of color in Figures 1-3 highlights the challenge in definitively identifying the border of DAWM, leading to the difficulty in determining and accurately quantifying its volume. Thus, given the quality of our historical MRI data, our approach was to use the skills of three very experienced MRI radiologists to visually identify changes in DAWM area. Future studies on higher field strength scanners may enable threshold-based approaches for semiautomatic DAWM identification, and more quantitative DAWM volume assessments, which could then be monitored longitudinally for changes in size.
An interesting and somewhat unexpected observation was that the detection rate of DAWM varied with field strength. At .5 T, DAWM was reported in only 8% of patients, while at 1.0 T DAWM was observed in 19-20% of patients and at 1.5 T 27-33% patients showed DAWM. While it is expected that images collected at lower field strength will be less able to detect small lesions, 40 DAWM encompasses much larger areas, so differences between .5 and 1.5 T from a spatial resolution standpoint does not explain the discrepancy. Whether the increased T 1 at higher field strength and associated change in T 1 -weighting contributes to the increased visibility of DAWM at higher fields is unknown, but further study into this finding is warranted. Given the long follow-up that ranged between 7.0 and 7.9 years, not unexpectedly, not all patients were scanned on the same scanner. At LTF, no patients were scanned at .5 T (75% at 1.5 T and 25% at 1.0 T), whereas at baseline 22% of the patients were scanned at .5 T (61% at 1.5 T and 17% at 1.0 T). Based on the finding that DAWM was identified more often on higher field strength, increase in the number of patients with DAWM could have been expected but in fact, of the 260 patients without DAWM at baseline, only 3 (1.2%) had developed DAWM at LTF and of the 88 patients with DAWM at baseline, at LTF, DAWM increased in only 2 (2.3%) patients and remained unchanged in 61 patients (69.3%) and decreased in 25 (28.4%; including 3 patients in which DAWM had disappeared). Finally, as mentioned, we evaluated clinical disability only in terms of physical measures (EDSS score), limiting our ability to assess for other clinical correlates of DAWM and its evolution over time.
Despite these limitations, this study provides new information on the prevalence of DAWM in MS and its relevance to disease severity and progression in a large cohort of patients with RRMS with approximately 8 years of follow up using standardized MRI techniques and clinical evaluations. This is the first long-term study to examine the prevalence of DAWM and its relationship to disease burden, changes in brain volume, and clinical disability. DAWM is a common finding in MS and rarely develops de novo in the later stages of the disease course. DAWM is an important predictor of MRI BOD progression and brain atrophy, but does not correlate with physical disability. Our study suggests that DAWM, given its fairly static nature, may indicate a subpopulation of MS patients, perhaps with an underlying phospholipid disorder or lymphatic pathology. Future studies correlating DAWM with cognitive measures will be of great interest and assessments of DAWM with quantitative methods may enable measurement of subtle changes over time.
